Table 1.
Parameter | Total n = 80 | Controls n = 38 | EB Cases n = 42 | p-Value | Corrected p-Value * |
---|---|---|---|---|---|
Anti-skin antibodies, U/mL | |||||
DSG1 | 2.72 (0–38.83) | 2.12 (0–15.09) | 3.83 (0.18–38.83) | 0.005 | 0.008 |
DSG3 | 2.8 (0–40.4) | 1.58 (0.08–8.38) | 3.72 (0–40.4) | <0.001 | <0.001 |
BP180 | 3.9 (0–118.8) | 1.82 (0–34.41) | 7.1 (0.5–118.8) | <0.001 | <0.001 |
BP230 | 3.55 (0.22–66) | 1.68 (0.22–26.74) | 4.75 (0.5–66) | <0.001 | <0.001 |
COL7 | 0.8 (0–41.05) | 0.26 (0–3.99) | 1.92 (0–41.05) | <0.001 | <0.001 |
Cytokines, pg/mL | |||||
IL-1β | 5.79 (0.88–192.67) | 2.75 (0.88–189.66) | 16.62 (1.16–192.67) | <0.001 | <0.001 |
IL-2 | 61.55 (8.01–3992.66) | 31.61 (8.01–2400) | 111.23 (18.76–3992.66) | <0.001 | <0.001 |
IL-4 | 0.96 (0.79–4.5) | 0.95 (0.8–2.07) | 0.96 (0.79–4.5) | 0.319 | 0.342 |
IL-6 | 15.12 (4.46–1000) | 8.54 (4.46–1000) | 33.44 (5.32–1000) | <0.001 | <0.001 |
IL-8 | 39.92 (12.96–939.06) | 27.96 (12.96–939.06) | 45.09 (13.14–449) | 0.171 | 0.197 |
IL-10 | 28.88 (5.86–250) | 21.12 (5.86–250) | 32.98 (8–250) | 0.006 | 0.008 |
IL-12 | 1.46 (1–9.21) | 1.36 (1–7.29) | 1.52 (1.14–9.21) | 0.045 | 0.056 |
TNF-α | 176.1 (128.17–4800) | 176.1 (128.17–1351.09) | 175.12 (137.66–4800) | 0.385 | 0.385 |
TNF-β | 1538.24 (802.84–36,000) | 1267.11 (802.84–3764.79) | 1737.07 (1101.8–36,000) | <0.001 | <0.001 |
IFN-γ | 220.68 (73.56–5000) | 176.34 (73.56–910) | 330.16 (79.18–5000) | 0.001 | 0.002 |
BP180: antibodies against bullous pemphigoid 180; BP230: antibodies against bullous pemphigoid 230; COL7: type VII collagen; DSG1: antibodies against desmoglein 1; DSG3: antibodies against desmoglein 3; EB: inherited epidermolysis bullosa; IFN: interferon; IL: interleukin; TNF: tumor necrosis factor. Median values (range in parentheses). * p-Values were adjusted for multiple testing using the false discovery rate method (with the Benjamini-Hochberg procedure).